hero image

Statement: Biogen Statement On Qui Tam Settlement

September 26, 2022 Company Statements

Biogen has reached a final agreement to pay $900 million to resolve previously disclosed qui tam litigation relating to speaker and consultant programs conducted by the Company prior to 2015. Biogen believes its intent and conduct was at all times lawful and appropriate and Biogen denies all allegations raised in this case. The U.S. and the states did not intervene in the case and the settlement does not include any admission of liability by Biogen.

Biogen determined that now was the right time to resolve the litigation and allow the Company to remain focused on our patients and strategic priorities. Biogen continues to believe that it is important to equip physicians and patients with the information needed to make the best decisions for their care.*

*The above includes forward-looking statements, which speak only as of the date they were made. Please consult the risk factors section of our SEC filings.

thumb
December 9, 2022
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)

CAMBRIDGE, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced that the U.S. Food and Drug Administration (FDA) has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA® 1 (tocilizumab), an

thumb
December 6, 2022
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Zuranolone is being evaluated as a short course, rapid-acting, oral medication for major depressive disorder (MDD) and postpartum depression (PPD)     Cambridge, Mass. – Dec. 6, 2022 – Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics (Nasdaq: SAGE) announced the completion of the rolling submission